Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and safety during after study drug injection.
Description: Proportion of patient with negative conversion in nasopharyngeal swab specimen based on reverse transcription quantitative polymerase chain reaction(RT-qPCR)or cell culture at each visit.
Measure: To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II) Time: Up to Day 14Description: Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture
Measure: To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II) Time: Up to Day 14Description: Time to clinical recovery
Measure: To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II) Time: Up to Day 14Description: Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection
Measure: To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II) Time: Up to Day 28Description: Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection
Measure: To evaluate the therapeutic efficacy CT-P59 for Part 2 (Phase III) Time: Up to Day 28Description: Proportion of patients requiring supplemental oxygen due to SARS-CoV-2 infection.
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patients with intensive care unit transfer due to SARS-CoV-2 infection
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patients with all-cause mortality
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Time to clinical recovery
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Duration of fever defined as the last day in the patient diary on which the temperature >38°C (100.4°F) is recorded, or a potentially antipyretic drug (acetaminophen or ibuprofen) is taken
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patients with hospital admission due to SARS-CoV-2 infection
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of mechanical ventilation due to SARS-CoV-2 infection
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patients requiring additional prescription medication due to SARS-CoV-2 infection
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patient with negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture
Measure: To evaluate the overall efficacy of CT-P59 for Part 1 and 2 Time: Up to Day 14 and 28Description: Proportion of patients reporting Adverse events (AEs, including serious adverse events)
Measure: To evaluate the overall safety of CT-P59 for Part 1 and 2 Time: Up to Day 90Description: Proportion of patients reporting Adverse events of special interest (Infusion related reactions, hypersensitivity and anaphylactic reactions)
Measure: To evaluate the overall safety of CT-P59 for Part 1 and 2 Time: Up to Day 90Description: Incidence of ADE (Antibody Dependent Enhancement)
Measure: To evaluate the overall safety of CT-P59 for Part 1 and 2 Time: Up to Day 90Description: Proportion of patients with anti-drug antibodies Immunogenicity
Measure: To evaluate the overall safety of CT-P59 for Part 1 and 2 Time: Up to Day 90Description: Proportion of patients with anti-drug antibodies S evere Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection related signs and symptoms.
Measure: To evaluate the overall safety of CT-P59 for Part 1 and 2 Time: Up to Day 90Description: Viral shedding in nasopharyngeal swab specimen based on RT-qPCR and cell culture
Measure: To evaluate virology for part 1 and part 2 Time: Up to Day 90Description: Genotype and phenotype of SARS-CoV-2 viral isolates
Measure: To evaluate virology for part 1 and part 2 Time: Up to Day 90Description: Viral serology for SARS-CoV-2 antibody
Measure: To evaluate virology for part 1 and part 2 Time: Up to Day 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports